UnitedHealth Group shares plunge 18% on reported DOJ probe into possible Medicare fraud

UnitedHealth Group shares plunge 18% on reported DOJ probe into possible Medicare fraud


Bloomberg | Bloomberg | Getty Images

Shares of UnitedHealth Group plunged more than 18% on Thursday following a report that the Justice Department is conducting a criminal investigation into the health-care giant over possible Medicare fraud.

The DOJ is focusing on the company’s Medicare Advantage business practices, but the exact nature of the potential criminal allegations is unclear, the Wall Street Journal reported late Wednesday, citing people familiar with the matter. 

In a statement, UnitedHealth Group said the Justice Department has not notified it about the reported probe, and called the newspaper’s reporting “deeply irresponsible.”

The company also said “we stand by the integrity of our Medicare Advantage program.”

It marks the second time the insurer’s Medicare Advantage business has come under federal scrutiny this year. The Journal reported in February that the DOJ is carrying out a civil investigation into whether the company inflated diagnoses to trigger extra payments to its Medicare Advantage plans. 

The reported investigation also follows the surprise exit of UnitedHealth Group CEO Andrew Witty, who will be replaced by the company’s former longtime chief executive, Stephen Hemsley. 

Shares of UnitedHealth Group are down roughly 49% this year following a string of setbacks for the company.

UnitedHealth Group has lost over $300 billion of its $600 billion market cap in just one month, Jared Holz, Mizuho health care equity strategist, said in an email on Thursday. He said there is some risk that the company will be removed from the Dow Jones Industrial Average “at some point unless there is greater evidence of greater consistency.”

UnitedHealth Group also had a tumultuous last year, grappling with a historic cyberattack, higher-than-expected medical costs and the torrent of public blowback after the murder of UnitedHealthcare’s CEO Brian Thompson.



Source

JPMorgan’s top biotech and pharma picks for the second half
Health

JPMorgan’s top biotech and pharma picks for the second half

Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. […]

Read More
How twin sister triathletes doubled down on sports success to raise health-startup millions from investors
Health

How twin sister triathletes doubled down on sports success to raise health-startup millions from investors

During their last year of completing work for doctoral degrees in physiology, twin sisters Michal Mor and Merav Mor started to compete in Ironman triathlon races. The demand for peak fitness led them to the realize the importance of understanding personal metabolism, and the lack of data being collected on it through devices accessible to […]

Read More
It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech
Health

It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech

Two graduate students research chemical products in a laboratory in Xiwangzhuang Town, Zaozhuang City, Shandong province of China, on Dec. 26, 2023. Nurphoto | Nurphoto | Getty Images BEIJING — For all the attention on U.S.-China competition in artificial intelligence, new studies point to China’s rapid rise in biotechnology, especially for drug and agricultural development. […]

Read More